Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/22545
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Joppa, Pavol | - |
dc.contributor.author | Tkacova, Ruzena | - |
dc.contributor.author | Franssen, Frits M. E. | - |
dc.contributor.author | Hanson, Corrine | - |
dc.contributor.author | Rennard, Stephen I. | - |
dc.contributor.author | Silverman, Edwin K. | - |
dc.contributor.author | McDonald, Merry-Lynn N. | - |
dc.contributor.author | Calverley, Peter M. A. | - |
dc.contributor.author | Tal-Singer, Ruth | - |
dc.contributor.author | SPRUIT, Martijn A. | - |
dc.contributor.author | Kenn, Klaus | - |
dc.contributor.author | Wouters, Emiel F. M. | - |
dc.contributor.author | Rutten, Erica P. A. | - |
dc.date.accessioned | 2016-11-09T08:53:59Z | - |
dc.date.available | 2016-11-09T08:53:59Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 17(8), p. 712-718 | - |
dc.identifier.issn | 1525-8610 | - |
dc.identifier.uri | http://hdl.handle.net/1942/22545 | - |
dc.description.abstract | Background: Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO). Objective: To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD. Design/Settings/Participants: Baseline data collected from a total of 2548 participants (2000 patients with COPD, mean age (SD), 63.5 (7.1) years; and 548 controls, 54.8 (9.0) years) from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, a multicenter longitudinal observational study, were used. Measurements: All participants were divided into 4 body composition phenotypes using bioelectrical impedance analysis: (1) normal body composition, (2) obesity, (3) sarcopenia, and (4) SO. In patients with COPD, the 6-minute walking distance, disease-specific health status, and plasma inflammatory markers were compared among the respective body composition groups. Results: Patients with COPD were 3 times more likely to present with SO compared with controls without COPD (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.0-5.4, P <.001). In patients with COPD, SO was related to reduced 6-minute walking distance (-28.0 m, 95% CI -45.6 to -10.4), P <.01) and to higher systemic inflammatory burden (an elevation of at least 2 inflammatory markers, OR 1.6, 95% CI 1.1-2.5, P =.028) compared with the normal body composition group after adjustments for age, sex, smoking, body mass index, and airflow limitation. Conclusions: Our findings suggest that SO is associated with worse physical performance and higher systemic inflammatory burden compared with other body composition phenotypes in patients with COPD. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine. | - |
dc.description.sponsorship | SIR has been an employee of AstraZeneca, and has served as a consultant, participated in advisory boards, received honorarium for speaking or grant support from American Board of Internal Medicine, Advantage Healthcare, Almirall, American Thoracic Society, AstraZeneca, Baxter, Boehringer Ingelheim, Chiesi, ClearView Healthcare, Cleveland Clinic, Complete Medical Group, CSL, Dailchi Sankyo, Decision Resources, Forest, Gerson Lehman, Grifols, GroupH, Guidepoint Global, Haymarket, Huron Consulting, Inthought, Johnson and Johnson, Methodist Health System-Dallas, NCI Consulting, Novartis, Pearl, Penn Technology, Pfizer, Planning-Shop, PSL FirstWord, Qwessential, Takeda, and WebMD; EKS has received honoraria and consulting fees from Merck, grant support and consulting fees from GlaxoSmithKline, and honoraria from Novartis; MNM has no conflict of interest to declare; PMAC has received consulting fees from AstraZeneca, GlaxoSmithKline, Nycomed, and Pfizer, speaking fees from GlaxoSmithKline and Nycomed, and grant support from Boehringer Ingelheim and GlaxoSmithKline; RT-S has been an employee and a shareholder of GlaxoSmithKline, the sponsor of ECLIPSE; MAS has no conflict of interest to declare; KK has received honoraria and consulting fees from GlaxoSmithKline, Takeda, Boehringer Ingelheim, Almirall, Chiesi, and AstraZeneca; EFMW has received honoraria and consulting fees from GlaxoSmithKline, Takeda, Boehringer Ingelheim, Almirall, Chiesi, and AstraZeneca; EPAR has no conflict of interest to declare. PJ received research support from the European Respiratory Society, No. STRTF 2013-2399. The ECLIPSE study (GSK Study No. SCO10490, NCT00292552) was funded by GlaxoSmithKline. | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.rights | © 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine. | - |
dc.subject.other | body composition; sarcopenic obesity; chronic obstructive pulmonary disease; 6-minute walking distance; fibrinogen; systemic inflammation | - |
dc.subject.other | Body composition; sarcopenic obesity; chronic obstructive pulmonary disease; 6-minute walking distance; fibrinogen; systemic inflammation | - |
dc.title | Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 718 | - |
dc.identifier.issue | 8 | - |
dc.identifier.spage | 712 | - |
dc.identifier.volume | 17 | - |
local.format.pages | 7 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Joppa, Pavol; Tkacova, Ruzena] Safarik Univ, Dept Resp Med, Kosice, Slovakia. [Joppa, Pavol; Franssen, Frits M. E.; Spruit, Martijn A.; Wouters, Emiel F. M.; Rutten, Erica P. A.] CIRO, Dept Res & Educ, Horn, Netherlands. [Hanson, Corrine] Univ Nebraska Med Ctr, Coll Allied Hlth Profess, Med Nutr Educ, Omaha, NE USA. [Rennard, Stephen I.] Univ Nebraska Med Ctr, Div Pulm Crit Care Sleep & Allergy, Omaha, NE USA. [Rennard, Stephen I.] AstraZeneca, Clin Discovery Unit, Cambridge, England. [Silverman, Edwin K.; McDonald, Merry-Lynn N.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA USA. [Silverman, Edwin K.] Harvard Med Sch, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA USA. [Calverley, Peter M. A.] Univ Liverpool, Pulm & Rehabil Med, Liverpool, Merseyside, England. [Tal-Singer, Ruth] GlaxoSmithKline, King Of Prussia, PA USA. [Spruit, Martijn A.] Hasselt Univ, Fac Med & Life Sci, BIOMED Biomed Res Inst, REVAL Rehabil Res Ctr, Diepenbeek, Belgium. [Kenn, Klaus] Schoen Klin Berchtesgadener Land, Dept Resp Med & Pulm Rehabil, Schoenau, Germany. [Wouters, Emiel F. M.] Maastricht Univ, Dept Resp Med, Maastricht, Netherlands. | - |
local.publisher.place | New York | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1016/j.jamda.2016.03.020 | - |
dc.identifier.isi | 000380759700008 | - |
item.fullcitation | Joppa, Pavol; Tkacova, Ruzena; Franssen, Frits M. E.; Hanson, Corrine; Rennard, Stephen I.; Silverman, Edwin K.; McDonald, Merry-Lynn N.; Calverley, Peter M. A.; Tal-Singer, Ruth; SPRUIT, Martijn A.; Kenn, Klaus; Wouters, Emiel F. M. & Rutten, Erica P. A. (2016) Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease. In: JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 17(8), p. 712-718. | - |
item.fulltext | With Fulltext | - |
item.validation | ecoom 2017 | - |
item.accessRights | Restricted Access | - |
item.contributor | Joppa, Pavol | - |
item.contributor | Tkacova, Ruzena | - |
item.contributor | Franssen, Frits M. E. | - |
item.contributor | Hanson, Corrine | - |
item.contributor | Rennard, Stephen I. | - |
item.contributor | Silverman, Edwin K. | - |
item.contributor | McDonald, Merry-Lynn N. | - |
item.contributor | Calverley, Peter M. A. | - |
item.contributor | Tal-Singer, Ruth | - |
item.contributor | SPRUIT, Martijn A. | - |
item.contributor | Kenn, Klaus | - |
item.contributor | Wouters, Emiel F. M. | - |
item.contributor | Rutten, Erica P. A. | - |
crisitem.journal.issn | 1525-8610 | - |
crisitem.journal.eissn | 1538-9375 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
joppa2016.pdf Restricted Access | In press | 515.54 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
26
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
73
checked on Sep 28, 2024
Page view(s)
50
checked on Sep 7, 2022
Download(s)
42
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.